<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES 
      EXCHANGE ACT OF 1934 

For the quarterly period ended   March 31, 1999
                               ------------------
                                       OR

[ ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES 
       EXCHANGE ACT OF 1934
For the transition period from              to 
                               ------------     ---------------



Commission file number                   1-7335
                      -------------------------------------------------------


                            LEE PHARMACEUTICALS
-------------------------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)


        California                                       95-2680312
---------------------------------                ------------------------------
(State or other jurisdiction of                        (I.R.S. Employer
 incorporation or organization)                       Identification No.)


           1444 Santa Anita Avenue, South El Monte, California 91733
--------------------------------------------------------------------------------
              (Address of principal executive offices) (Zip Code)

                               (626) 442-3141
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

                                      N/A
--------------------------------------------------------------------------------
               (Former name, former address and former fiscal year,
                       if changed since last report)

         Indicate by check mark whether the registrant has (1) filed all 
reports required to be filed by Section 13 or 15(d) of the Securities 
Exchange Act of 1934 during the preceding 12 months (or for such shorter 
period that the registrant was required to file such reports), and (2) has 
been subject to such filing requirements for the past 90 days.
Yes  X   No   
    ---    ---
       As of March 31, 1999 there were outstanding 4,135,162 shares of common 
stock of the registrant.

         Transitional Small Business Disclosure Format (check one):
Yes     No  X 
    ---    ---

<PAGE>

                               LEE PHARMACEUTICALS
                                  BALANCE SHEET
                                 MARCH 31, 1999
                             (DOLLARS IN THOUSANDS)
                                   (UNAUDITED)
<TABLE>
<S>                                                                   <C>              <C>
                        ASSETS
Cash                                                                                    $    5

Accounts and notes receivable (net of allowances: $201)                                  1,155

Due from related party                                                                     103

Inventories:
     Raw materials                                                   $ 1,636
     Work in process                                                     247
     Finished goods                                                      364
                                                                     -------
     Total inventories                                                                   2,247

Other current assets                                                                       412
                                                                                        ------
     Total current assets                                                                3,922

Property, plant and equipment (less
     accumulated depreciation and
     amortization: $6,242)                                                                 466

Goodwill and other assets (net of
     accumulated amortization: $6,214)                                                   2,741
                                                                                        ------

        TOTAL                                                                           $7,129
                                                                                        ------
                                                                                        ------
</TABLE>
                       See notes to financial statements.


<PAGE>

                               LEE PHARMACEUTICALS
                                  BALANCE SHEET
                                 MARCH 31, 1999
                             (DOLLARS IN THOUSANDS)
                                   (UNAUDITED)
              LIABILITIES
<TABLE>
<S>                                                                                    <C>
Bank overdraft                                                                          $   32
Note payable to bank                                                                     1,285
Notes payable, other                                                                       856
Current portion - royalty agreements                                                        58
Current portion - note payable related party                                               435
Accounts payable                                                                         1,343
Other accrued liabilities                                                                  518
Environmental cleanup liability                                                            288
Due to related parties                                                                     525
Deferred income                                                                             65
                                                                                        ------
         Total current liabilities                                                       5,405
                                                                                        ------
Long-term notes payable to related parties                                               2,685
                                                                                        ------
Long-term notes payable, other                                                             907
                                                                                        ------
Long-term notes payable to bank                                                            205
                                                                                        ------
Environmental cleanup liability - Casmalia Site                                            374
                                                                                        ------
Deferred income                                                                             44
                                                                                        ------
         COMMITMENTS AND CONTINGENCIES

         STOCKHOLDERS' EQUITY

Common stock, $10 per value; authorized, 7,500,00 shares;
    issued and outstanding, 4,135,162 shares.                                              413

Additional paid-in capital                                                               4,222

Accumulated deficit                                                                     (7,126)
                                                                                        ------
         Total stockholders' equity                                                     (2,491)
                                                                                        ------
           TOTAL                                                                        $7,129
                                                                                        ------
                                                                                        ------
</TABLE>
                       See notes to financial statements.

<PAGE>

                               LEE PHARMACEUTICALS

                            STATEMENTS OF OPERATIONS
                (DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
                                                    FOR THE THREE MONTHS                FOR THE SIX MONTHS
                                                       ENDED MARCH 31,                    ENDED MARCH 31,

                                                   1999             1998             1999              1998 
                                                ----------      -----------       -----------      -----------
                                                (UNAUDITED)      (UNAUDITED)      (UNAUDITED)      (UNAUDITED)
<S>                                             <C>              <C>               <C>              <C>
Gross revenues                                    $ 2,636         $  2,215         $  4,769         $  4,851
Less:    Sales returns                               (133)            (197)            (260)            (357)
         Cash discounts and others                    (21)             (18)             (37)             (41)
                                                  -------         --------         --------         --------
Net revenues                                        2,482            2,000            4,472            4,453
                                                  -------         --------         --------         --------
Costs and expenses:

       Cost of sales                                1,027              857            1,963            1,880
       Selling and advertising expense                820              859            1,539            1,789
       General and administrative expense             344              422              647              784
       Interest expense                               186              153              374              300
                                                  -------         --------         --------         --------
Total costs and expenses                            2,377            2,291            4,523            4,753
                                                  -------         --------         --------         --------
Income (loss) from operations                         105             (291)             (51)            (300)

Other income                                           19               18               34               36
                                                  -------         --------         --------         --------
Net income (loss) before extraordinary
       item                                           124             (273)             (17)            (264)

Extraordinary loss related to Casmalia
       Disposal Site cleanup                            -                -             (374)               -
                                                  -------         --------         --------         --------


Net income (loss)                                 $   124         $   (273)        $   (391)        $   (264)
                                                  -------         --------         --------         --------
                                                  -------         --------         --------         --------

Per share:

       Net income (loss) per share before
          extraordinary loss                      $   .03         $   (.06)        $    .00         $   (.06)

       Extraordinary loss                             .00              .00             (.09)             .00
                                                  -------         --------         --------         --------
       Net income (loss)                          $   .03         $   (.06)        $   (.09)        $   (.06)
                                                  -------         --------         --------         --------
                                                  -------         --------         --------         --------
</TABLE>
                       See notes to financial statements.


<PAGE>

                               LEE PHARMACEUTICALS
                            STATEMENTS OF CASH FLOWS
                             (DOLLARS IN THOUSANDS)
<TABLE>
<CAPTION>
                                                                                     FOR THE SIX MONTHS
                                                                                       ENDED MARCH 31,

                                                                                      1999         1998   
                                                                                   ----------   ----------
                                                                                   (UNAUDITED)  (UNAUDITED)
<S>                                                                                 <C>            <C>
Cash flows from operating activities:
   Net loss...................................................................    $   (391)     $   (264)
     Loss from extraordinary item.............................................         374            --
                                                                                  --------      --------
   Net (loss) before extraordinary item.......................................         (17)         (264)
                                                                                  --------      --------
   Adjustments to reconcile net (loss) to net
    cash used in operating activities:
   Depreciation...............................................................          67            57
   Amortization of intangables................................................         423           477
   (Decrease) in deferred income..............................................         (33)          (33)
   (Gain) on disposal of property, plant, and equipment.......................          (2)           (4)
Change in operating assets and liabilities:
   (Increase) decrease in accounts receivable.................................        (261)          439
   (Increase ) in due from related party......................................         (45)         (105)
   (Increase) in inventories .................................................        (125)         (177)
   Decrease in other current assets...........................................          91           481
   Increase (decrease) in accounts payable....................................         285          (194)
   Increase in accounts payable related party.................................          51           100
   Increase (decrease) in notes payable, other................................         712           (64)
   Increase in other accrued liabilities......................................         118           270
   (Decrease) in accrued royalities...........................................        (329)         (709)
                                                                                  --------      --------
   Total adjustments..........................................................         952           538
                                                                                  --------      --------
     Net cash provided by operating activities................................         935           274
                                                                                  --------      --------
Cash flows from investing activities:
   Additions to property, plant, and equipment................................         (49)          (38)
   Proceeds from sale of equipment............................................           2             4
   Acquisitions of product brands.............................................        (930)          (70)
                                                                                  --------      --------
     Net cash (used in) investing activities..................................        (977)         (104)
                                                                                  --------      --------
Cash flows from financing activities:
   (Payments on) bank loans...................................................         (12)         (136)
   (Payments on) notes payable to related party...............................          (2)          (64)
   Proceeds from notes payable, other.........................................          73           200
   (Decrease) in long-term royalty agreements.................................           -           (80)
   (Decrease) in bank overdraft...............................................         (54)          (90)
                                                                                  --------      --------
     Net cash provided by (used in) financing activities......................           5          (170)
                                                                                  --------      --------
Net (decrease)  increase in cash..............................................         (37)            0
Cash, beginning of year.......................................................          42            26
                                                                                  --------      --------
Cash end of period............................................................    $      5      $     26
                                                                                  --------      --------
                                                                                  --------      --------
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
   Interest...................................................................    $    309      $    249
                                                                                  --------      --------
                                                                                  --------      --------
Acquisitions of product brands:
   Fair value of assets acquired..............................................    $    997      $     70
   Fair value of liabilities incurred.........................................         (67)           --
                                                                                  --------      --------
     Net cash payments........................................................    $    930      $     70
                                                                                  --------      --------
                                                                                  --------      --------
</TABLE>
                                         See notes to financial statements.
<PAGE>

     NOTES TO FINANCIAL INFORMATION

1.   Basis of presentation:

     The accompanying balance sheet as of March 31, 1999, and the statements of
     operations and cash flows for the periods ended March 31, 1999, and 1998,
     have not been audited by independent accountants but reflect all
     adjustments, consisting of any normal recurring adjustments, which are, in
     the opinion of management, necessary to a fair statement of the results for
     such periods. The results of operations for the six months ended March 31,
     1999, are not necessarily indicative of results to be expected for the year
     ending September 30, 1999.

     Certain information and footnote disclosure normally included in financial
     statements prepared in accordance with generally accepted accounting
     principles have been omitted pursuant to the requirements of the Securities
     and Exchange Commission, although the Company believes that the disclosures
     included in these financial statements are adequate to make the information
     not misleading.

     The financial statements should be read in conjunction with the financial
     statements and notes thereto included in the Company's annual report on
     Form 10-KSB for the fiscal year ended September 30, 1998.

     The Company is involved in various matters involving environmental cleanup
     issues. See "Item 2. Management's Discussion and Analysis or Plan of
     Operations" and Note 10 of Notes to Financial Statements included in the
     Company's Form 10-KSB for the fiscal year ended September 30, 1998. The
     ultimate outcome of these matters cannot presently be determined.
     Environmental expenditures that relate to an existing condition caused by
     past operations, and which do not contribute to current or future revenue
     generation, are expensed. The Company's proportionate share of the
     liabilities are recorded when environmental remediation and/or cleanups are
     probable, and the costs can be reasonably estimated.

     The Company accrued a $374,000 charge in the first quarter of fiscal 1999
     with respect to a possible environmental cleanup liability related to the
     Casmalia Disposal Site. The Company will be filing for relief from this
     obligation under the financial hardships option in the EPA's response form
     "Instructions for Applying for Financial Review," consequently, the
     $374,000 accrual is presented as a long-term liability.

2.   Continued existence:

     The accompanying financial statements have been prepared assuming that the
     Company will continue as a going concern. The Company's recurring past
     losses from operations and inability to generate sufficient cash flow from
     normal operations raise substantial doubt about its ability to continue as
     a going concern. The financial statements do not include any adjustments to
     reflect the possible future effects on the recoverability and
     classification of assets or the amounts and classification of liabilities
     that may result from the possible inability of the Company to continue as a
     going concern.

3.   Net income (loss) per share:

     Net income (loss) per share is based on the weighted average number of
     shares of common stock outstanding during the periods presented. Common
     stock equivalents (common stock options) are not included in these
     calculations where their effect on net income per share is anti-dilutive.
     The weighted average number of shares was 4,135,162 for all periods
     presented.

4.   Note payable to bank:

     Effective April 26, 1996, the Company renewed its real estate loan with the
     bank. The note payable to the bank, secured by deed on land and building,
     requires a monthly payment of $4,200 including interest at the bank's
     reference rate plus 4%, maturing March 2001. At March 31, 1999, the
     interest rate was 11.75%. The note is guaranteed by the former Chairman of
     the Company and the Company's President.


<PAGE>

5.   Line of credit:

     Effective May 21, 1998, the Company renewed its accounts receivable
     financing, maturing May 2000, whereby 75% of the eligible domestic accounts
     receivable, not to exceed $1,100,000 less amounts loaned on inventory, not
     to exceed $400,000, can be advanced. The agreement may be renewable for
     successive one year periods thereafter. Also, the agreement requires
     minimum monthly interest of $3,000 with an interest rate of 5% above Bank
     of America's prime rate. The new financing agreement includes a $400,000
     term loan on inventory which is incorporated in the working capital line of
     credit above. The term loan requires monthly payments of $11,110 with an
     interest rate of 6% above Bank of America's prime rate. Additionally, there
     is a separate $440,000 term loan on the Company's equipment. The financing
     is secured by a security interest in all of the Company's assets and
     requires monthly payments of $11,800 including interest at Bank of
     America's prime rate plus 6%.

6.   Acquisition:

     On February 17, 1998, the Company purchased certain assets of the
     PAIN-A-LAY-R- throat spray line from Medtech Laboratories, Inc. for
     $70,000. The Company is required to make five payments of $14,000 each plus
     interest at 10% starting 61 days after the close. In addition, the Company
     purchased for cash inventory valued at $27,764.

     On September 28, 1998, the Company purchased certain assets of the
     EVAC-U-GEN-R- brand of laxatives from Walker, Corp. & Co., Inc. for
     $234,000. The Company remitted $100,000 at closing and is required to make
     monthly payments of $5,300, plus interest, beginning November 25, 1998 and
     ending September 25, 2001. This note is personally guaranteed by the
     Company's Chairman. The interest rate is equal to the highest prime rate
     during any one period. In addition, the Company purchased certain
     inventories from Walker, Corp. & Co., Inc. for $54,500 at closing.

     On October 1, 1998, the Company purchased certain assets of the Cheracol-R-
     cough syrup, Comhist-R- decongestant tablets and Entuss-R- expectorant
     product lines from Roberts Pharmaceutical Corporation for $684,934. The
     Company remitted $600,000 at closing and is required to make monthly
     payments of $3,538, plus interest at prime, commencing January 1, 1999, and
     ending November 1, 2000. In addition, the Company purchased certain
     inventory for $150,800 for which the Company is required to make monthly
     payments of $6,283, plus interest at prime, commencing January 1, 1999, and
     ending November 1, 2000. By mutual consent, the buyer and seller, in March,
     1999 reduced the purchase price to $666,863 and the monthly payments were
     adjusted from $3,538 to $2,786. The maturity date is unchanged.

     On December 1, 1998, the Company purchased certain assets of seven
     over-the-counter products from Numark Laboratories, Inc. for $430,000 of
     which $100,000 was inventory. The Company remitted the full $430,000 at
     closing.

7. Non-cash transaction:

     In March 1999 a non-cash transaction was recorded whereby $193,000 in prior
     cash advances, to a related party, was offset against a long-term note, of
     the same amount, due to the same related party.

<PAGE>

ITEM 2.

     MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

     MATERIAL CHANGES IN RESULTS OF OPERATIONS
     THREE MONTHS ENDED MARCH 31, 1999, AND MARCH 31, 1998

     Gross revenues for the three months ended March 31, 1999, were $2,636,000,
     an increase of approximately $421,000 or 19% from the comparable three
     months ended March 31, 1998. The increase in gross revenues was due to the
     new volume generated from the newly acquired brands such as; EVAC-U-GEN-R-,
     Cheracol-R-, Comhist-R-, and Entuss-R- as well as other new
     over-the-counter items. The newly acquired brands accounted for
     approximately $349,000 of the $421,000 increase stated above. The Company
     also had increases in other brands namely; Aquafilter-R-, Lee-R- Lip-Ex-TM-
     and other over-the-counter items. The above mentioned increases were offset
     by a reduction ($119,000) in gross revenues of the nail extender category.

     Net revenues increased approximately $482,000 or 24% for the three months
     ended March 31, 1999, as compared to the three months ended March 31, 1998.
     The change in net revenues was due to the same explanations discussed
     above. The Company's sales returns decreased approximately $64,000 or 32%
     when comparing fiscal years 1999 and 1998, due mainly to lower returns of
     the depilatory category and several over-the-counter items.

     Cost of sales as a percentage of gross revenues was 39% for the three
     months ended March 31, 1999 and March 31, 1998.

     Selling and advertising expenses decreased $39,000 or 5% when comparing the
     three months ended March 31, 1999, with the three months ended March 31,
     1998. The decrease in expenses was mainly due to the following factors; 1)
     finalization of a minimum royalty due ($125,000 per quarter) on a brand
     acquisition which ended on September 30, 1998 and 2) lower commissions
     ($31,000) due to fewer sales representatives and lower commission rates.
     The above decreases were somewhat offset by increases in; 1) amortization
     expense ($18,000) the result of recent brand acquisitions, 2) products
     liability insurance ($11,000) due to an increase in coverage limits, 3)
     cooperative advertising/advertising expenses ($45,000), 4) salaries and
     wages plus related fringe benefits the result of new hires and increased
     salaries and wages ($21,000) and 5) freight costs ($22,000).

     General and administrative expenses decreased $78,000 or 18% when comparing
     the three months ended March 31, 1999, with the three months ended March
     31, 1998. The decrease in expanses was mainly due to the following factors;
     1) lower salaries and wages plus related fringe benefits ($63,000), 2)
     reduced legal expenses ($25,000) and 3) a reduction in temporary help
     expense ($8,000). The decreases were partially offset by an increase in
     management information systems (MIS) consulting services ($45,000) related
     to electronic data interchange (EDI) and Year 2000 readiness.

     Interest expense increased $33,000 or 22% when comparing the three months
     ended March 31, 1999, with the three months ended March 31, 1998. The
     increase was due to increased borrowings from the Company's asset based
     financing lender and additional liability commitments as a result of recent
     brand acquisitions and higher private borrowings at a higher interest rate.
     This was somewhat offset by a decrease in the prime rate, 7.75% versus 8.5%
     at March 31, 1999 and March 31, 1998, respectively related to certain
     borrowings which are tied to prime.

     MATERIAL CHANGES IN RESULTS OF OPERATIONS
     SIX MONTHS ENDED MARCH 31, 1999, AND MARCH 31, 1998

     Gross revenues for the six months ended March 31, 1999, were $4,769,000, a
     decrease of approximately $82,000 or 2% from the comparable six months
     ended March 31, 1998. The decease in gross revenues was due to the decline
     in volume generated from the depilatory category, Aquafilter-R- and the
     nail extender category of products. The decreased sales volume was
     partially offset by the sales revenues generated from the newly acquired
     brands such as; EVAC-U-GEN-R-, Cheracol-R-, Comhist-R-, and Entuss-R- as
     well as other new over-the-counter items.


<PAGE>

     Net revenues for the six months ended March 31, 1999 were $4,472,000, an
     increase of $19,000 from the comparable six months ended March 31, 1998.
     The sales returns were lower ($97,000 or 27%) during the six months period
     ended March 31, 1999, versus March 31, 1998. This was the result of lower
     returns of the nail extender products, depilatory category and several
     over-the-counter brands.

     Cost of sales as a percentage of gross revenues for the six months ended
     March 31, 1999, as compared to the six months ended March 31, 1998, was 41%
     versus 39% respectively. The higher cost of sales percentage for the six
     months ended March 31, 1999, compared to March 31, 1998 was due to
     additional personnel (wages plus related fringe benefits), higher freight
     costs and off pricing to several retailers.

     Selling and advertising expenses decreased $250,000 or 14% when comparing
     the six months ended March 31, 1999, with the six months ended March 31,
     1998. The decreased expenses were basically due to; 1) finalization of a
     minimum royalty due ($250,000 for six months) on a brand acquisition which
     ended September 30, 1998, and 2) lower commissions ($82,000) due to fewer
     manufacturer representatives and lower commission rates. The decreases were
     partially offset by increases in; 1) amortization expense ($33,000), 2)
     products liability insurance ($16,000) due to an increase in coverage
     limits, 3) advertising expenses ($46,000), 4) salaries and wages plus
     related fringe benefits the result of new hires and increased salaries and
     wages ($50,000), and 5) a joint venture cost related to a recent brand
     acquisition ($25,000).

     General and administrative expenses decreased $137,000 or 17% when
     comparing the six months ended March 31, 1999, with the six months ended
     March 31, 1998. This decrease was principally due to the same factors
     outlined above when comparing the three months ended March 31, 1999, versus
     the comparable period ended March 31, 1998.

     Interest expense increased $74,000 or 25% when comparing the six months
     ended March 31, 1999, with the six months ended March 31, 1998. The
     increase was due to the explanation outlined above when comparing the three
     months ended March 31, 1999 versus the comparable period ended March 31,
     1998.

     LIQUIDITY AND CAPITAL RESOURCES

     During the three months ended March 31, 1999, working capital was a
     negative $1,483,000 compared with a negative $719,000 as of September 30,
     1998. The ratio of current assets to current liabilities was .7 to 1 at
     March 31, 1999, and .8 to 1 at September 30, 1998. The increase in the
     Company's negative working capital was basically due to a decease in other
     current assets and increases in notes payable to bank.

     The Company has an accumulated deficit of $7,126,000. The Company's past
     recurring losses and the second quarter 1999's profit and fiscal 1997's
     nominal profit from operations and inability to generate sufficient cash
     flow from normal operations to meet its obligations as they came due raise
     substantial doubt about the Company's ability to continue as a going
     concern. The Company's ability to continue in existence is dependent upon
     future developments, including retaining current financing and achieving a
     level of profitable operations sufficient to enable it to meet its
     obligations as they become due.

     YEAR 2000 READINESS

     Most companies have computer systems that use two digits to identify a year
     in the date field (e.g. "98" for 1998). These systems must be modified to
     handle turn-of-the century calculations. If not corrected, systems failures
     or miscalculations could occur, potentially causing disruptions of
     operations, including, among other things, the inability to process
     transactions, send invoices, or engage in other normal business activities.
     This creates potential risk for all companies, even if their own computer
     systems are Year 2000 compliant.

     In 1998, the Company initiated a comprehensive review of its computer
     systems to identify processes that could be adversely affected by Year 2000
     issues. In addition, the Company identified computer application systems
     that required modification or replacement.

<PAGE>

     The Company will be required to modify or replace certain portions of its
     software so that its systems will function properly with respect to dates
     in the Year 2000 and thereafter. The Company has upgraded its existing
     computer system hardware and software and has solicited the assistance of a
     software reengineering company specializing in services to resolve the Year
     2000 problem to remediate non-compliant code in existing applications and
     systems. The Company is also utilizing internal resources to reprogram or
     replace and test the software for Year 2000 modifications.

     The Company has an ongoing program of communicating with suppliers and
     vendors to determine the extent to which those companies are addressing
     Year 2000 compliance issues. There can be no assurance that the Company
     will be able to develop a contingency plan that will adequately address
     issues that may arise in the Year 2000.

     In 1999, a contingency plan will be developed in the event key or critical
     suppliers or vendors are unable to meet the Year 2000 compliance. If
     needed, such steps as identifying alternative suppliers and vendors will be
     addressed. The timeframe for completing or documenting contingency plans
     has not been finalized.

     The Company estimates that the cost of remediation will be less than
     $100,000. The remediation costs include internal labor costs, as well as
     fees and expenses paid to outside contractors specifically associated with
     programming and purchased hardware and upgraded software.

     The Company's Year 2000 plans, including costs, preparation for testing,
     and completion schedules (by October 1999), are based on management's best
     estimates. These estimates were derived using assumptions of future events
     including third party input, availability of qualified personnel, and other
     factors.

     Based on currently available information, management does not believe that
     the Year 2000 matters discussed above will have a material adverse impact
     on the Company's financial condition or results of operations; however,
     because of the uncertainties in this area, no assurances can be given in
     this regard.

     ENVIRONMENTAL MATTERS

     The Company owns a manufacturing facility located in South El Monte,
     California. The California Regional Water Quality Control Board (The
     "RWQCB") ordered the Company in 1988 and 1989 to investigate the
     contamination on its property (relating to soil and groundwater
     contamination). The Company engaged a consultant who performed tests and
     reported to the then Chairman of the Company. The Company resisted further
     work on its property until the property upgradient was tested in greater
     detail since two "apparent source" lots had not been tested. On August 12,
     1991, the RWQCB issued a "Cleanup and Abatement Order" directing the
     Company to conduct further testing and cleanup the site. In October 1991,
     the Company received from an environmental consulting firm an estimate of
     $465,200 for investigation and cleanup costs. The Company believed that
     this estimate was inconclusive and overstated the contamination levels. The
     Company believes that subsequent investigations will support the Company's
     conclusions about that estimate. The Company did not complete the testing
     for the reasons listed above as well as "financial constraints". In June
     1992 the RWQCB requested that the EPA evaluate the contamination and take
     appropriate action. At the EPA's request, Ecology & Environment, Inc.
     conducted an investigation of soil and groundwater on the Company's
     property. Ecology & Environment Inc.'s Final Site Assessment Report, which
     was submitted to the EPA in June 1994, did not rule out the possibility
     that some of the contamination originated on-site, and resulted from either
     past or current operations on the property. The Company may be liable for
     all or part of the costs of remediating the contamination on its property.
     The EPA has not taken any further action in this matter, but may do so in
     the future.

     The Company and nearby property owners, in consort with their comprehensive
     general liability (CGL) carriers, have engaged a consultant to perform a
     site investigation with respect to soil and shallow groundwater
     contamination over the entire city block. The CGL carriers provided
     $290,000 in funding which paid for the $220,000 study, $20,000 in legal
     fees for project oversight, and a $50,000 balance in the operating fund.
     Earlier the Company had accrued $87,500 as its proportionate share of the
     earlier quote of $175,000. Since that time, the overall scope of the
     project was increased to $205,000 plus $15,000 for waste water disposal,
     bringing the total to the above listed $220,000. The $87,500 accrual was
     not spent on this project (as the entire cost was borne by the CGL
     carriers), but remains on the books as an accrual against the cost of
     remediation of the same site that was included in the study.


<PAGE>

     The tenants of nearby properties upgradient have sued the Company alleging
     that hazardous materials from the Company's property caused contamination
     on the properties leased by the tenants. The case name is DEL RAY
     INDUSTRIAL ENTERPRISES, INC. v. ROBERT MALONE, ET AL., Los Angeles County
     Superior Court, Northwest District, commenced August 21, 1991. In this
     action, the plaintiff alleges environmental contamination by defendants of
     its property, and seeks a court order preventing further contamination and
     monetary damages. The Company does not believe there is any basis for the
     allegations and is vigorously defending the lawsuit.

     The Company's South El Monte manufacturing facility is also located over a
     large area of possibly contaminated regional groundwater which is part of
     the San Gabriel Valley Superfund site. The Company has been notified that
     it is a potentially responsible party ("PRP") for the contamination. In
     1995, the Company was informed that the EPA estimated the cleanup costs for
     the South El Monte's portion of the San Gabriel Valley Superfund site to be
     $30 million. The Company's potential share of such amount has not been
     determined. Superfund PRPs are jointly and severally liable for superfund
     site costs, and are responsible for negotiating among themselves the
     allocation of the costs based on, among other things, the outcome of
     environmental investigation.

     In August 1995 the Company was informed that the EPA entered into an
     Administrative Order of Consent with Cardinal Industrial Finishes
     ("Cardinal") for a PRP lead remedial investigation and feasibility study
     (the "Study") which, the EPA states, will both characterize the extent of
     groundwater contamination in South El Monte and analyze alternatives to
     control the spread of contamination. The Company and others have entered
     into the South El Monte Operable Unit Site Participation Agreement with
     Cardinal pursuant to which, among other things, Cardinal will contract with
     an environmental firm to conduct the Study. The Study has been completed
     but the final program has not been reported. The Company's share of the
     cost of the Study is currently $15,000 and was accrued for in the financial
     statements as of September 30, 1995.

     The City of South El Monte, the city in which the Company has its
     manufacturing facility, is located in the San Gabriel Valley. The San
     Gabriel Valley has been declared a Superfund site. The 1995 Water Quality
     Control Plan issued by the California Regional Water Quality Control Board
     states that the primary groundwater basin pollutants in the San Gabriel
     Valley are volatile organic compounds from industry, nitrates from
     subsurface sewage disposal and past agricultural activities. In addition,
     the Plan noted that hundreds of underground storage tanks leaking gasoline
     and other toxic chemicals have existed in the San Gabriel Valley. The
     California Department of Toxic Substance Control have declared large areas
     of the San Gabriel Valley to be environmentally hazardous and subject to
     cleanup work.

     The Company believes the City of South El Monte does not appear to be
     located over any of the major plumes. However, the EPA recently announced
     it is studying the possibility that, although the vadose soil and
     groundwater, while presenting cleanup problems, there may be a
     contamination by DNAPs (dense non-aqueous phase liquids), i.e., "sinkers",
     usually chlorinated organic cleaning solvents. The EPA has proposed to
     drill six "deep wells" throughout the City of South El Monte at an
     estimated cost of $1,400,000. The EPA is conferring with SEMPOA (South El
     Monte Property Owners Association) as to cost sharing on this project.
     SEMPOA has obtained much lower preliminary cost estimates. The outcome cost
     and exact scope of this are unclear at this time.

     The Company and other property owners engaged Geomatrix Consultants, Inc.,
     to do a survey of vadose soil and shallow groundwater in the "hot spots"
     detected in the previous studies. Geomatrix issued a report dated December
     1, 1997 (the "Report"), on the impact of volatile organic compounds on the
     soil and groundwater at the Lidcombe and Santa Anita Avenue site located in
     South El Monte, California (which includes the Company's facilities). The
     Report indicated generally low concentrations of tetrachloroethene,
     trichloaethene and trichloroethane in the groundwater of the upgradient
     neighbor. The Report was submitted to the RWQCB for its comments and
     response. A meeting with the parties and RWQCB was held on February 10,
     1998. The RWQCB had advised companies that vadose soil contamination is
     minimal and requires no further action. However, there is an area of
     shallow groundwater which has a higher than desired level of chlorinated
     solvents, and the RWQCB requested a proposed work plan be submitted by
     Geomatrix. Geomatrix has submitted a "Focused Feasibility Study" which
     concludes that there are five possible methods for cleanup. The most
     expensive are for a pump and sewer remediation which would cost between
     $1,406,000 and $1,687,000. The Company is actively exploring the less
     expensive alternative remediation methods, of which the two proposed
     alternatives range in cost between $985,000 and $1,284,000. Accordingly,
     the Company has taken the average of the two amounts ($985,000 and
     $1,284,000) as

<PAGE>

     the total amount of estimated cost. Since there are four economic entities
     involved, the Company's best estimate at this time, in their judgment,
     would be that their forecasted share would be 25% or $284,000 less the
     liability already recognized on the books of $162,000 thereby requiring an
     additional $122,000 liability. Accordingly, the Company recorded an
     additional accrual of $122,000 in the third quarter of fiscal 1998. The
     $122,000 accrual is in addition to the $79,000 accrual for the Monterey
     Site as will be explained in the following paragraph. The $79,000 accrual,
     in the third quarter of fiscal 1998, related to the Monterey Site is not
     included in the $284,000 figure above. No assurances can be given that any
     of the alternative remediation methods will be feasible or that the actual
     cost to the Company of the remediation will not exceed the amount of the
     Company's current accruals of $284,000 (which includes the $122,000 charge
     to income in the third quarter of fiscal 1998).

     Without any prior correspondence or inkling of the Company's potential
     liability, the EPA has recently informed the Company that the Company may
     have potential liability for the ongoing remediation of Operating
     Industries, Inc. (as they have gone out of business) Landfill Superfund
     Site in Monterey Park, California (the "Monterey Site"). The Monterey Site
     is a 190 acre landfill that operated from 1948 to 1984, in which the
     Company disposed of non toxic pH balanced waste water on six occasions
     between 1974 and 1978. Over 4,000 companies have been identified as having
     contributed waste to the Monterey Site. The EPA has offered to settle the
     Company's potential liability with respect to the Monterey Site for a cost
     to the Company of $79,233. The Company accrued a $79,000 charge in the
     third quarter of fiscal 1998 with respect to this possible liability. The
     Company has elected to file for relief from these obligations under the
     financial hardship option in the EPA's response form.

     The Company was recently notified by the EPA that the Company may have
     potential liability for waste material it disposed of at the Casmalia
     Disposal Site ("Site") located on a 252-acre parcel in Santa Barbara
     County, California. The Site was operational from 1973 to 1989 and over
     10,000 separate parties disposed of waste there. The EPA stated that
     federal, state and local governmental agencies along with the numerous
     private entities that used the Site for waste disposal will be expected to
     pay their share as part of this settlement. The U.S. EPA is also pursuing
     the owner(s)/operator(s) of the Site to pay for Site remediation. The EPA
     has a settlement offer to the Company with respect to the Site for a cost
     of $373,950. The Company accrued a $374,000 charge in the first quarter of
     fiscal 1999 with respect to this possible liability. The Company has
     elected to file for relief from these obligations under the financial
     hardships option in the EPA's response form "Instructions for Applying for
     Financial Review."

     The total amount of environmental investigation and cleanup costs that the
     Company may incur with respect to the foregoing is not known at this time.
     However, based upon information available to the Company at this time, the
     Company has expensed since 1988 a total of $860,000, of which $89,000 were
     legal fees, exclusive of legal fees expended in connection with the SEC
     environmental investigation. The actual costs could differ materially from
     the amounts expensed for environmental investigation and cleanup costs to
     date.


<PAGE>

                           PART II - OTHER INFORMATION

Item 1.   Legal Proceedings

The information set forth under Part I, Item 2, "Management's Discussion and
Analysis or Plan of Operations Environmental Matters" is incorporated herein by
reference. See also "Legal Proceedings" in the Company's Form 10-KSB for the
fiscal year ended September 30, 1998.

Item 4.   Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of the registrant occurred on March 9, 1999.
At that meeting, the following directors were elected:

<TABLE>
<CAPTION>
                                                                        VOTES
                                                               -----------------------
      Director                                                    FOR         WITHHELD
                                                                  ---         --------
      <S>                                                      <C>            <C>
      Dr. Henry L. Lee                                         3,178,815       129,795
      Ronald G. Lee                                            3,178,815       137,795
      William M. Caldwell IV                                   3,179,447       129,163
</TABLE>

<TABLE>
<CAPTION>
                                                                      VOTES
                                                         -----------------------------
                                                          FOR       AGAINST    ABSTAIN
<S>                                                       <C>        <C>        <C>
The appointment of George Brenner, CPA
  as independent auditor                                  3,213,797   53,666    41,147
</TABLE>


Item 6.       Exhibits

              3.1 - Articles of Incorporation, as amended (1)

              3.4 - By-laws, as amended December 20, 1997 (2)

              3.5 - Amendment of By-laws effective March 14, 1978 (2)

              3.6 - Amendment to By-laws effective November 1, 1980 (3)

             27   - Financial Data Schedule

              (1)   Filed as an Exhibit of the same number with the Company's
                    Form S-1 Registration Statement filed with the Securities
                    and Exchange Commission on February 5, 1973, (Registrant No.
                    2-47005), and incorporated herein by reference.

              (2)   Filed as Exhibits 3.4 and 3.5 with the Company's Form 10-K
                    Annual Report for the fiscal year ended September 30, 1978,
                    filed with the Securities and Exchange Commission and
                    incorporated herein by reference.

              (3)   Filed as an Exhibit of the same number with the Company's
                    Form 10-K Annual Report for the fiscal year ended September
                    30, 1979, filed with the Securities and Exchange Commission
                    and incorporated herein by reference.

<PAGE>

                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Acts of 1934,
the registrant has caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                                   LEE PHARMACEUTICALS
                                          -------------------------------------
                                                       (Registrant)

Date:      May 6, 1999                                 RONALD G. LEE
      ---------------------               -------------------------------------
                                                       Ronald G. Lee
                                          Chairman of the Board, President and
                                          Chief Financial and Accounting Officer